Every 8-K that Silvaco Group, Inc. (SVCO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SVCO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SVCO filings page.
Silvaco Group, Inc. entered into a Convertible Note Purchase Agreement with Micron Technology, Inc. under which Silvaco issued an unsecured $10.0 million Senior Convertible Promissory Note bearing 8.0% simple interest, with no periodic cash payments, in a private placement.
All outstanding principal and accrued interest will automatically convert to common stock on August 7, 2028, or immediately before a Change of Control, at the lower of 90% of the stock’s fair market value on the Conversion Date or 115% of the closing price before the Note date, subject to a Nasdaq share issuance cap. If that cap is exceeded, part of the note converts and the remainder is settled in cash, potentially including a prepayment penalty. While the note is outstanding, Silvaco’s ability to incur additional debt is limited to an aggregate of $50.0 million of subordinated indebtedness for borrowed money and certain finance leases, and Micron may receive registration rights for any conversion shares under specified conditions.
Silvaco Group, Inc. reported strong second quarter 2026 momentum, with revenue of $17.8 million, up 48% year-over-year. TCAD contributed $7.9 million, EDA $3.9 million, and SIP $6.0 million, with SIP revenue rising 238% year-over-year. GAAP gross margin improved to 85%, and the GAAP net loss narrowed to $3.7 million, or $0.11 per share. Cash and cash equivalents were $13.0 million at June 30, 2026.
On a non-GAAP basis, Silvaco achieved its first non-GAAP operating profit in almost two years, generating $0.6 million of non-GAAP operating income and $0.3 million of non-GAAP net income ($0.01 per share). Gross bookings were $16.2 million, up 25% year-over-year. IP bookings reached $5.4 million, up 81% sequentially and 70% year-over-year, while IP revenue rose to $6.0 million. The company highlighted record pipeline creation, with $64 million in new opportunities and a total identified pipeline above $292 million.
Strategically, Silvaco expanded partnerships with NVIDIA and Dassault Systemes SIMULIA around digital twin workflows and deepened its relationship with Micron Technologies through a $10 million convertible note tied to its AI-driven FTCO platform. Management introduced Agentic AI offerings and cited expectations for additional FTCO wins, more AI offerings, anticipated record revenue in Q4, and double-digit revenue growth again in 2027. For third quarter 2026, Silvaco guides to bookings of $18.0 million ±10%, revenue of $17.0 million ±10%, non-GAAP gross margin around 88%, and non-GAAP operating expenses of $14.5 million ±5%.
Silvaco Group, Inc. filed a prospectus supplement covering the offer and sale of 69,062 shares of its common stock to John Cary, a former equityholder of Tech-X Corporation. These shares are being issued as part of the consideration for Silvaco’s acquisition of Tech-X, satisfying contingent earnout milestones and post-closing adjustment amounts in lieu of cash.
The shares are issued under Silvaco’s effective shelf registration statement on Form S-3 (File No. 333-291212), declared effective on November 21, 2025. Silvaco states it will not receive any cash proceeds from this share issuance.
Silvaco Group, Inc. has changed its independent registered public accounting firm. On May 21, 2026, the company dismissed Baker Tilly US, LLP, and on May 27, 2026, engaged KPMG LLP as its new auditor, following a decision by the Board’s Audit Committee.
The filing states there were no disagreements with Baker Tilly on accounting principles, financial disclosures, or audit scope for the years ended December 31, 2025 and 2024 and the interim period through May 21, 2026. It references a previously disclosed material weakness in internal control over financial reporting related to a lack of formalized processes and insufficient technically skilled personnel, as described in the company’s Form 10-K for the year ended December 31, 2024. Baker Tilly’s audit reports for 2025 and 2024 contained no adverse opinions or disclaimers, and Baker Tilly provided a letter to the SEC concurring with the company’s statements.
Silvaco Group, Inc. expanded its at-the-market common stock offering program to a total of $35.0 million under its existing Open Market Sale Agreement with Jefferies LLC. This includes an additional $20.0 million capacity above the previously registered amount.
As of May 7, 2026, the company had sold 752,744 shares for approximately $4,331,280, leaving up to $30,668,720 of common stock available to be offered and sold. Based on a share price of $12.46 and 14,066,661 non‑affiliate shares, the public float was $175,270,596, so Silvaco is no longer subject to the “baby shelf” limitation and may now use General Instruction I.B.1 of Form S‑3.
Silvaco Group, Inc. reported strong first quarter 2026 results, with revenue of $17.8 million, up 26% year-over-year, and gross bookings of $17.2 million, also up 26%. Growth was led by SIP revenue of $4.0 million, up 270% year-over-year, and TCAD revenue of $9.6 million, up 22%, while EDA revenue declined to $4.1 million, down 20%.
GAAP gross margin improved to 86%, and the GAAP net loss narrowed to $5.9 million from $19.3 million a year earlier. On a non-GAAP basis, net loss was reduced to $0.6 million, or $0.02 per share, versus a $2.4 million loss, or $0.08 per share, in the prior-year quarter. Cash and cash equivalents were $10.9 million at quarter-end.
The company highlighted growing traction for its AI FTCO™ offering and a broader AI-focused product strategy. For the second quarter of 2026, Silvaco expects bookings of about $19.0 million, revenue of about $18.0 million, and non-GAAP gross margin around 88%, with non-GAAP operating expenses of roughly $15.5 million.
Silvaco Group, Inc. held its Annual Meeting of Stockholders on April 22, 2026. As of the February 25, 2026 record date, 31,423,487 shares of common stock were outstanding and entitled to vote, and 23,250,295 shares, or about 74%, were represented in person or by proxy.
Stockholders elected all nominated directors to serve until the 2027 annual meeting or until their successors are elected and qualified. Vote totals for individual nominees ranged from approximately 17.5 million to 23.1 million shares cast “for,” with relatively low withhold levels and no broker non-votes reported for these items.
Silvaco Group, Inc. established an at-the-market equity program allowing it to sell shares of common stock with an aggregate offering price of up to $15.0 million through Jefferies LLC as sales agent.
Sales will be made from time to time under an effective Form S-3 shelf registration and related prospectus supplement, with Jefferies earning up to 3.0% of the gross sales price on shares sold. Either party may suspend or terminate the offering, and Silvaco is not obligated to sell any shares under this agreement.
Silvaco Group reported mixed fourth quarter and full-year 2025 results as it pursues a turnaround strategy. Q4 2025 revenue was $18.3 million, up 2% year over year, with strong SIP growth to $5.1 million (up 483%) offset by a 31% decline in TCAD revenue to $8.8 million. Q4 GAAP net loss was $7.2 million versus $4.2 million net income a year earlier, while non-GAAP net loss was $0.8 million compared with $4.0 million non-GAAP net income.
For 2025, revenue grew 6% to $63.1 million, driven by 60% EDA growth and 98% SIP growth, but GAAP net loss widened slightly to $41.2 million and non-GAAP swung to an $11.1 million loss from $5.5 million income. Management highlighted acquisitions, a cost reduction program targeting $20 million in annualized non-GAAP operating expense savings (with $14 million executed by year-end), and guidance for Q1 2026 revenue and bookings of $15–$19 million, non-GAAP gross margin around 85%, and non-GAAP operating expenses of $14.5–$16.5 million.
Silvaco Group, Inc. updated its corporate governance by adopting Amended and Restated Bylaws, effective February 13, 2026. The board of directors approved these changes to align the stockholder approval threshold required for removing directors with the threshold already set out in the company’s Amended and Restated Certificate of Incorporation.
The detailed terms of the new bylaws are contained in the Amended and Restated Bylaws filed as Exhibit 3.2, which are incorporated by reference. This change focuses on consistency between the company’s core governing documents rather than altering its business operations or financial position.
Silvaco Group, Inc. filed a prospectus supplement covering the offer and sale of 167,281 shares of its common stock to John Cary, a former equityholder of Tech-X Corporation. These shares are being issued as part of the consideration for Silvaco’s acquisition of Tech-X.
The stock issuance satisfies contingent earnout obligations tied to developmental milestones and a portion of additional purchase consideration from post-closing adjustments, in each case in lieu of cash. The shares are offered under Silvaco’s effective Form S-3 shelf registration statement, and the company will not receive any cash proceeds from this issuance.
Silvaco Group, Inc. is undertaking a targeted Restructuring program started in October 2025 to streamline its organizational structure, improve execution, and enhance stockholder value. As part of this effort, the company announced an initial involuntary reduction in force in the United States on November 24, 2025, alongside a voluntary early retirement program, a voluntary exit program, further planned involuntary reductions, and certain site closures.
Silvaco currently estimates it will record pre-tax GAAP charges ranging from $2 million to $5 million, primarily for severance, one-time termination benefits, and costs related to site closures under its global site strategy. The majority of affected employees are expected to be terminated by December 31, 2025, with the Restructuring expected to be substantially completed in fiscal year 2026, subject to various execution risks and uncertainties.
Silvaco Group, Inc. (SVCO) furnished an 8-K announcing quarterly results. On November 12, 2025, the company issued a press release with financial results for the third fiscal quarter ended September 30, 2025, and posted related supplemental financial information on its website. The press release was furnished as Exhibit 99.1 under Item 2.02 and, as stated, is not deemed “filed” for purposes of Section 18 of the Exchange Act unless expressly incorporated by reference.
Silvaco Group, Inc. announced that Christopher Zegarelli will join as Chief Financial Officer effective September 15, 2025. His base salary is $450,000 and he is eligible for a $400,000 sign-on bonus paid in two $200,000 installments, the first payable within 30 days of the start date and subject to repayment if he voluntarily resigns or is terminated for cause before January 1, 2027. The second installment is contingent on achieving fiscal 2026 revenue and profit targets at or above 100% of plan and continued service through December 31, 2026. He is eligible for an annual incentive target equal to 60% of base salary, prorated for 2025, with payment based on company-wide performance and at the Board's discretion. He will receive RSUs equal to $2,300,000 in value with 1/4 vesting after one year and the balance vesting quarterly to fully vest at year four. He is eligible for the Executive Severance Plan and an indemnification agreement. The company disclosed the appointment via a press release furnished as Exhibit 99.1.
Silvaco Group, Inc. reported a CEO transition and related compensation arrangements. Dr. Babak A. Taheri stepped down as CEO and director, effective August 19, 2025, and entered a Separation Agreement providing severance and other benefits. Under that agreement he will receive aggregate cash severance of $975,484 (equal to 18 months' base salary plus pro‑rata target bonus), COBRA health benefit payments for 15 months, accelerated vesting of 126,161 unvested time‑based restricted stock units, 12 months of car lease payments totaling $12,000, and payment of a $20,000 life insurance premium. The agreement also preserves confidentiality, non‑disparagement and non‑solicit covenants and includes a release of claims.
The Board appointed Dr. Walden C. Rhines as CEO, effective August 19, 2025, and the company entered an employment agreement through March 31, 2027. Dr. Rhines will receive an annual base salary of $160,000 and may receive performance‑based restricted stock unit grants with grant‑date fair values ranging from $100,000 up to an aggregate of $6,252,636, vesting upon achievement of specified VWAP trading thresholds and continued employment through the Term. If terminated under certain conditions before or at the end of the Term, Dr. Rhines may be eligible for a lump sum severance ranging from $500,000 to $1,000,000 and accelerated vesting of PRSUs, subject to a release and covenant compliance.